SNY Stock Analysis: Buy, Sell, or Hold?
SNY - Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
$43.16
1.53 (3.68%)
▲
5d:
+3.25%
30d:
+0.84%
90d:
-9.57%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 30, 2026
25d
Get Alerted When SNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SNY shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: SNY shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$58.98
Based on 5.1% avg growth
INTRINSIC VALUE TODAY
$36.62
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNY is currently trading at $43.16, which is considered fair relative to its 30-day fair value range of $42.20 to $44.29. The stock's valuation (Forward PE: 8.2) is in line with its historical norms (8.7). Remarkably, the market is currently pricing in an annual earnings decline of 2.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SNY is in a strong downtrend. The price is approaching resistance at $43.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $55.90 (+29.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SNY is in a strong downtrend. The price is approaching resistance at $43.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $55.90 (+29.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$42.20 -
$44.29
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 29.5% below Wall St target ($55.90)
Trading Range Analysis
30-Day Trading Range
$42.20 -
$44.29
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$40.89
Resistance Level
$43.48
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.16
Wall Street Target
$55.90
(+29.5%)
Revenue Growth (YoY)
6.0%
Earnings Growth (YoY)
-11.7%
Profit Margin
16.0%
Valuation Discount vs History
-2.2% cheaper
PE vs Historical
8.2 vs 8.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.2%
(market-implied from PE analysis)
1-Year Target
$42.21
(-2%)
2-Year Target
$41.28
(-4%)
3-Year Target
$40.37
(-7%)
3-Yr Target (if PE normalizes)
(PE: 8→9)
$43.03
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 6.2%)
$137.87
(+219%)
Base:
(SPY PE: 8.2, Growth: 6.2%)
$51.67
(+20%)
Bear:
(PE: 6.9, Growth: 6.2%)
$43.92
(+2%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 18.42 | Current EPS (TTM): $2.26
Bull Case
$91.59
(+112%)
Analyst growth 100.0%, PE expands to 20.3
Base Case
$83.26
(+93%)
Market implied 100.0%, PE stable at 18.4
Bear Case
$28.31
(-34%)
Severe decline -20.0%, PE contracts to 15.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.2 to 8.7
Stabilization Target:
$46.00
(+6.6%)
PE Expansion Potential:
+6.6%
Share & Embed Analysis
Last updated: July 04, 2026 1:13 AM ET
Data refreshes hourly during market hours. Next update: 2:13 AM
Data refreshes hourly during market hours. Next update: 2:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1223 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 67 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 69 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 67 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 60 HOLD |
